The hypoimmune iPSC field is moving faster than the regulatory frameworks around it
Universal donor cell therapy is closer than most people think. The bottleneck isn't the biology anymore.
Three observations from the past six months of work on our HIDE-iPSC platform:
The biology is ahead of the regulatory playbook. We can engineer iPSC lines with credible immune evasion profiles. What we can't yet do is point to a clear regulatory pathway for an allogeneic, hypoimmune, off-the-shelf cell therapy at IND. The FDA is engaged and thoughtful, but the frameworks are still being written in real time.
The CMC requirements are being underestimated. Demonstrating immune evasion in a dish is not the same as demonstrating it in a GMP-manufactured product at clinical dose. Release assays for hypoimmune function need to be validated, reproducible, and predictive of in vivo behavior. We are nowhere near consensus on what those assays look like.
The competitive dynamic is accelerating. At least four programs with credible hypoimmune iPSC approaches are now in or approaching IND-enabling studies. The window for establishing manufacturing leadership in this space is narrow.
The opportunity is real. So is the urgency.
Views expressed in this post are solely those of Dhruv Sareen in his personal and academic capacity and do not reflect the positions of any affiliated institution or organization. Full disclaimer
← Back to The Frontier